Literature DB >> 17996590

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

Robert A Kyle1, S Vincent Rajkumar.   

Abstract

In 1978, the term "monoclonal gammopathy of undetermined significance" (MGUS) was introduced. MGUS is defined as a serum monoclonal (M) protein less than 3.0 g/dL; less than 10% plasma cells in the bone marrow, if done; little or no M protein in the urine; and absence of lytic bone lesions, anemia, hypercalcemia or renal insufficiency. This article discusses the recognition, prevalence, natural history, and progression of MGUS. Management of the disease is discussed along with its association with other disorders. Information on smoldering multiple myeloma is included.

Entities:  

Mesh:

Year:  2007        PMID: 17996590     DOI: 10.1016/j.hoc.2007.08.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  14 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Genomic analysis of high-risk smoldering multiple myeloma.

Authors:  Lucía López-Corral; María Victoria Mateos; Luis A Corchete; María Eugenia Sarasquete; Javier de la Rubia; Felipe de Arriba; Juan-José Lahuerta; Ramón García-Sanz; Jesús F San Miguel; Norma C Gutiérrez
Journal:  Haematologica       Date:  2012-02-13       Impact factor: 9.941

Review 3.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

4.  A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Hyun Koo; Doo-Hwan Oh; Yeoun Sook Chun; Jae Chan Kim
Journal:  Korean J Ophthalmol       Date:  2011-05-24

5.  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance.

Authors:  Jad G Sfeir; Tito D Pena Guzman; Lucia Bedatsova; Stephen M Broski; Matthew T Drake
Journal:  Bone       Date:  2020-04-28       Impact factor: 4.398

Review 6.  Reconstructing the evolutionary history of multiple myeloma.

Authors:  Francesco Maura; Even H Rustad; Eileen M Boyle; Gareth J Morgan
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

7.  Diet-induced obesity promotes a myeloma-like condition in vivo.

Authors:  S T Lwin; S W Z Olechnowicz; J A Fowler; C M Edwards
Journal:  Leukemia       Date:  2014-10-07       Impact factor: 11.528

Review 8.  unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?

Authors:  Matthew T Drake
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

9.  The immune microenvironment of myeloma.

Authors:  Kimberly Noonan; Ivan Borrello
Journal:  Cancer Microenviron       Date:  2011-08-25

10.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.

Authors:  John A Lust; Martha Q Lacy; Steven R Zeldenrust; Angela Dispenzieri; Morie A Gertz; Thomas E Witzig; Shaji Kumar; Suzanne R Hayman; Stephen J Russell; Francis K Buadi; Susan M Geyer; Megan E Campbell; Robert A Kyle; S Vincent Rajkumar; Philip R Greipp; Michael P Kline; Yuning Xiong; Laurie L Moon-Tasson; Kathleen A Donovan
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.